Checkpoint Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

License Agreements (Details)

License Agreements (Details) - USD ($)	1 Months Ended	3 Months Ended
License Agreements (Details) - USD ($)	Mar. 31, 2015	Mar. 31, 2024	Feb. 28, 2023	Jan. 31, 2019	May 31, 2016
NeuPharma, Inc. \| Additional sales milestone
License Agreements
Maximum potential milestone payments	$ 40,000,000.0
NeuPharma, Inc. \| Clinical and development milestone
License Agreements
Maximum potential milestone payments	39,000,000.0
NeuPharma, Inc. \| Regulatory approvals to commercialize the products
License Agreements
Maximum potential milestone payments	22,500,000
Dana-Farber Cancer Institute
License Agreements
Amount of milestone expensed	5,000,000.0
Maintenance fee	50,000
Dana-Farber Cancer Institute \| First commercial sale milestone
License Agreements
Maximum potential milestone payments	21,500,000
Dana-Farber Cancer Institute \| Additional sales milestone
License Agreements
Maximum potential milestone payments	$ 60,000,000.0
Adimab, LLC \| PD-L1 \| Research and development
License Agreements
Non-Refundable milestone payment			$ 2,200,000
Adimab, LLC \| Regulatory approvals to commercialize the products
License Agreements
Maximum potential milestone payments				$ 2,500,000
Jubilant Biosys Limited \| Additional sales milestone
License Agreements
Maximum potential milestone payments					$ 89,300,000
Jubilant Biosys Limited \| Regulatory approvals to commercialize the products
License Agreements
Maximum potential milestone payments					59,500,000
Jubilant Biosys Limited \| Clinical development and regulatory milestones
License Agreements
Maximum potential milestone payments					$ 88,400,000
Collaboration Agreement With TGTX
License Agreements
Revenue recognition milestone revenue recognized		$ 29,000
Sublicense Agreement with TGTX
License Agreements
Revenue recognition milestone revenue recognized		$ 6,000